6 citations
,
February 2013 in “Medical Oncology” Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.
16 citations
,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
38 citations
,
December 2020 in “Cancers” Targeting Wnt signaling in gastrointestinal cancer therapy is promising but challenging due to potential side effects, requiring specific strategies and combination therapies.
17 citations
,
May 2019 in “Journal of International Medical Research” Xiaoaiping reduces chemotherapy side effects and improves quality of life for breast cancer patients.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
1 citations
,
July 2025 in “MedComm – Biomaterials and Applications” Microneedles show promise for cancer diagnosis and treatment due to their minimally invasive nature and effective drug delivery.
January 2026 in “Journal of Applied Pharmaceutical Science” Selaginella doederleinii extract shows potential for cervical cancer treatment but needs more research.
53 citations
,
November 2014 in “International Journal of Oncology” Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.
6 citations
,
April 2022 in “The Breast” Scalp cooling reduces hair loss during chemotherapy but doesn't help hair regrow after.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
54 citations
,
September 2012 in “Acta ophthalmologica” Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
7 citations
,
August 2022 in “Experimental dermatology” Blocking YAP/TAZ could be a new way to treat skin cancer.
6 citations
,
September 2024 in “Current Oncology” Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
5 citations
,
January 2024 in “BMC Cancer” Anthracycline and taxane chemotherapy cause significant side effects like fatigue, vomiting, nausea, nerve damage, joint pain, and hair loss in breast cancer patients.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
April 2025 in “Nutrients” Consult an oncologist before using supplements for hair loss during breast cancer treatment.
June 2019 in “Advanced medical journal” Cancer drugs often cause temporary hair, skin, nail, and mouth issues.
21 citations
,
April 2016 in “International Journal of Oncology” GnRH treatment can reduce breast cancer cell invasion.
11 citations
,
August 2017 in “Supportive care in cancer” Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.
10 citations
,
September 2021 in “JAMA Dermatology” Different types of persistent hair loss after chemotherapy respond differently to treatments.
December 2024 in “Cureus” Chemotherapy worsens nutritional status in breast cancer patients, requiring targeted nutritional strategies.
August 2024 in “Asian Journal of Research in Chemistry” Repurposing existing drugs can improve cancer treatment but faces challenges.
1 citations
,
January 2025 in “JAAD reviews.” Personalized hair care strategies are needed for Black cancer patients to prevent hair loss during chemotherapy.
388 citations
,
September 2000 in “Cancer” Doxil's toxicity varies with dose and schedule, and pharmacokinetic guidance can optimize dosing.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
12 citations
,
February 2019 in “Journal of patient-reported outcomes” Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.
4 citations
,
June 2025 in “MedComm” PROTACs show promise for cancer treatment, but designing them effectively is challenging.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.